RECRUITINGOBSERVATIONAL
Radiofrequency Ablation for BIII Thyroid Nodules
Radiofrequency Ablation for Indeterminate Bethesda III Thyroid Nodules
About This Trial
The purpose of this observational chart review study is to evaluate the efficacy and safety of Radiofrequency Ablation (RFA) for treatment of indeterminate thyroid nodules before and after RFA procedure. This is a data collection study in which the investigators ask patients to give access to information generated before and after RFA treatment of their condition. The RFA procedure uses image guidance to place an electrode through the skin into the target area. In RFA, high-frequency electrical currents are passed through an electrode, creating a small region of heat to treat the lesion.
Who May Be Eligible (Plain English)
Who May Qualify:
- Indeterminate Bethesda III nodules that have been molecularly profiled benign with either Afirma Genomic Sequencing Classifier (GSC) or ThyroSeq v3 tests
Who Should NOT Join This Trial:
- cardiac arrthymias
- pregnancy
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Indeterminate Bethesda III nodules that have been molecularly profiled benign with either Afirma Genomic Sequencing Classifier (GSC) or ThyroSeq v3 tests
Exclusion Criteria:
* cardiac arrthymias
* pregnancy
Treatments Being Tested
PROCEDURE
Radiofrequency Ablation
Ultrasound guided radiofrequency ablation (non-experimental)
Locations (1)
Columbia University
New York, New York, United States